A Clinical Study of PSK in Head and Neck Malignancy

DOI Web Site

Bibliographic Information

Other Title
  • ＰＳＫによる頭けい部悪性しゅようの治療成績
  • PSK ニヨル トウケイブ アクセイ シュヨウ ノ チリョウ セイセキ

Search this article

Abstract

A clinical study of PSK (protein-bound polysaccaride) was carried out in 169 patients with head and neck malignancy and the following results were obtained.<br>1. PSK was administered to 82 (48.5%) out of the 169 cases basically treated by irradiation and/or surgery.<br>2. The one year survival rate (95.0%) of patients with laryngeal cancer treated by irradiation combined with chemotherapy with or without PSK was better than that (45.2%) of patients solely treated by irradiation. On the other hand, the effect of antitumor agents including PSK on the malignant tumor of nose and paranasal sinuses was not evident.<br>3. The 18-month survival rate (63.6%) of patients with pharyngeal cancer who received supplementary administration of 5-FU or FT-207 combined with PSK was higher than that (16.7%) of patients treated only with 5-FU or FT-207. A similar effect of PSK was observed in the analysis of patients with oral cancer; the 18-month survival rate of patients supplementally treated with 5-FU or FT-207 combined with PSK was 66.7% and that of patients who received no PSK was 16.7%.<br>4. No side-effects of PSK were found in this series.<br>The present study indicates that various antineoplastic therapies for treatment of head and neck malignancy may produce good results when PSK is continuously administered concomitantly.

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top